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Abstract
Aneuploidy, a hallmark of cancer cells, poses an appealing
opportunity for cancer treatment and prevention strategies. Using
a cell-based screen to identify small molecules that could selec-
tively kill aneuploid cells, we identiﬁed the compound N-[2-
hydroxy-1-(4-morpholinylmethyl)-2-phenylethyl]-decanamide
monohydrochloride (DL-PDMP), an antagonist of UDP-glucose
ceramide glucosyltransferase. DL-PDMP selectively inhibited pro-
liferation of aneuploid primarymouse embryonic ﬁbroblasts and
aneuploid colorectal cancer cells. Its selective cytotoxic effects
werebasedon further accentuating the elevated levels of ceramide,
which characterize aneuploid cells, leading to increased apopto-
sis. We observed that DL-PDMP could also enhance the cytotoxic
effects of paclitaxel, a standard-of-care chemotherapeutic agent
that causes aneuploidy, in human colon cancer and mouse
lymphoma cells. Our results offer pharmacologic evidence that
the aneuploid state in cancer cells can be targeted selectively for
therapeutic purposes, or for reducing the toxicity of taxane-based
drug regimens. Cancer Res; 77(19); 5272–86. 2017 AACR.
Introduction
Aneuploidy, an abnormal karyotype characterized by gains and
losses of whole chromosomes, has a profound impact on human
health. Most constitutive autosome gains and all autosome losses
cause embryonic lethality. The few trisomies that survive to term
display severe abnormalities including developmental delays,
cognitive and organ defects, as well as a shortened lifespan.
Somatic aneuploidy is also associatedwith disease; it is a hallmark
of cancer. More than 90% of solid tumors harbor an aberrant
karyotype (1, 2).
The adverse effects of aneuploidy have been characterized.
Aneuploid mammalian and yeast cells exhibit proliferation
defects (3–5) and genomic instability (6–9). In addition, cells
harboring whole chromosome gains and losses displaymetabolic
alterations (5, 10) and experience proteotoxic stress, which is
caused by aneuploidy-induced changes in protein abundance that
place an increased demand on the cell's protein folding and
degradation machineries (3, 4, 11–13).
Because aneuploidy is a rare occurrence in normal tissues (14)
and even selected against in vivo (15), aneuploidy-associated
stresses represent a unique opportunity to speciﬁcally eliminate
cancer cells. A previously conducted, small scale, targeted proof-
of-principle screen showed that compounds indeed exist that
preferentially inhibit the growth of aneuploid cells (11) and
spurred the larger scale effort to identify aneuploidy-selective
compounds described here. Using trisomy 13 mouse embryonic
ﬁbroblasts (MEF), we identiﬁed DL-PDMP, an UDP-glucose
ceramide glucosyltransferase (UGCG) antagonist (16), to prefer-
entially inhibit the growth of primary aneuploid cells and highly
aneuploid colorectal cancer cells.
Ceramides belong to the sphingolipid family. These lipids play
a critical role in eukaryotic membrane biology and cell signaling.
Sphingolipids are synthesized de novo through the conjugation of
serine and palmitoyl-CoA to produce dihydrosphingosine, which
is then further condensed into dihydroceramide (Fig. 1; ref. 17).
Desaturation of dihydroceramide by dihydroceramide desaturase
facilitates the generation of ceramide (18). Ceramide serves as an
essential substrate for several different modiﬁcations (Fig. 1). The
modiﬁcations include phosphorylation to produce ceramide-1-
phosphate. Addition of a phosphocholine head group converts
ceramide into sphingomyelin, the major sphingolipid species in
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mammalian membranes (Fig. 1; ref. 19). Ceramide is also con-
verted into glucosylceramide through the addition of glucose by
glucosylceramide synthase. This sphingolipid is critical for the
production of more complex glycosphingolipids such as lacto-
sylceramide and gangliosides employed for cell–cell communi-
cation. Importantly, the production of sphingolipids is highly
dynamic, as members of this lipid family interconvert depending
on the cell's need. For example, sphingomyelin, glucosylcera-
mide, and sphingosine are interconverted via a ceramide inter-
mediate (Fig. 1).
In addition to their crucial role in membrane function, many
sphingolipids, such as ceramide, ceramide-1-phosphate (C1P),
sphingosine, and sphingosine-1-phosphate (S1P) are bioactive
signaling molecules that have been demonstrated to regulate
apoptosis, senescence, differentiation, proliferation, and inﬂam-
mation (19). Owing to the central role of sphingolipids in
membrane biology and cell signaling, sphingolipid pathways
have been considered as therapeutic targets in many diseases,
including obesity, type II diabetes, asthma, and Gaucher disease,
which is caused by loss of glucosylceramidase GBA1 activity
(20, 21). Targeting sphingolipid metabolism through sphingo-
sine kinase inhibitors has also been explored in the treatment of
cancers, such as glioblastoma, but off-target effects and side effects
of these kinase inhibitors remain a concern (22).
Here we describe the identiﬁcation of DL-PDMP, an UDP-
glucose ceramide glucosyltransferase antagonist (16), as selec-
tively inhibiting the proliferation of aneuploid primary cells and
highly aneuploid colorectal cancer cells. We show that this selec-
tivity is due to DL-PDMP further elevating already high levels of
ceramide in aneuploid cells, which leads to apoptosis. Genetic
manipulations that cause an increase in intracellular ceramide
levels are also detrimental to aneuploid primary cells and aneu-
ploid colorectal cancer cells. Finally, consistent with the idea that
increasing ceramide levels are especially detrimental to aneuploid
cells, we ﬁnd that in some cell types, DL-PDMP exhibits strong
synergistic antiproliferative effects with Taxol, a chemotherapeu-
tic that causes chromosomemis-segregation and hence aneuploi-
dy. Our results raise the exciting possibility that chemical inter-
ventions that lead to increased intracellular ceramide levels might
not only represent a new broad-spectrum anticancer agent but
could be combined with standard of care Taxane-based chemo-
therapy regimens to augment efﬁcacy and mitigate toxicity.
Materials and Methods
Mouse strains
All mouse strains were obtained from the Jackson Laboratory.
Strains used to generate trisomic embryos are: Rb(1.2)18Lub/J
and Rb(1.3)1Ei/J for Ts1; Rb(11.13)4Bnr/J and Rb(13.16)1Mpl/J
for Ts13; Rb(6.16)24Lub and Rb(16.17)7Bnr for Ts16; and Rb
(5.19)1Wh/J and Rb(9.19)163H for Ts19. All male compound
Robertsonian heterozygous mice were mated with C57BL/6J
females and embryos were collected at speciﬁc stages of embryo-
genesis by timed matings as described previously (5). All animal
studies and procedures were approved by MIT Institutional Ani-
mal Care and Use Committee.
Primary MEF cell lines
Littermate-derived euploid and trisomic primary MEFs were
prepared as described previously (5, 11). Experiments were
performed in at least three independent trisomic cell lines and
analyzed together with euploid littermates. MEFs were used
at early passages (p5) to ensure that their karyotypes had not
evolved. Two independent CDC20(AAA/AAA) MEF cell lines
were kindly provided by Dr. Pumin Zhang (Baylor College of
Medicine, Houston, TX) and BUB1b(H/H) mice by Dr. Jan van
Deursen (Mayo Clinic, Rochester, MN). MEFs were cultured
in DMEM (Invitrogen) supplemented with 10% FBS, 2 mmol/L
L-glutamine, and 100 U/mL penicillin/streptomycin. All cells
were maintained at 37C with 5% CO2 in a humidiﬁed envi-
ronment, and examined to ensure mycoplasma-free. All MEF
cell lines were authenticated by genotyping.
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Figure 1.
Ceramide biosynthesis pathways.
Ceramides are generated through
de novo synthesis in the endoplasmic
reticulum. In the de novo synthesis
pathway, serine palmitoyltransferase
converts serine and palmitate into
dihydrosphingosine. In a series of
reactions, dihydrosphingosine is
converted into ceramide. Complex
sphingolipids can also be degraded
into ceramide. In the salvage pathway,
sphingosine is metabolized into
ceramide by ceramide synthase, and
glucosylceramide is degraded into
ceramide by glucosyl ceramidase. In
the sphingomyelin hydrolysis
pathway, plasma membrane
sphingomyelin is hydrolyzed into
ceramide via sphingomyelinase.
Compounds that inhibit various
enzymes in the ceramide biosynthesis
pathway are shown in green.
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Human cell lines
All cancer cell lines and primary cell lines were obtained from
ATCC (May, 2011) and upon arrival, prepared early-passage cell
stocks to ensure all cell line experiments were analyzed within 10
further passages. The cell lines are human colorectal MIN lines
(HCT-116, HCT-15, DLD-1, SW48, and LoVo), human colorectal
CIN lines (Caco2, HT29, SW403, SW480, and SW620), leukemia
lines (Kasumi-1, Ku812, K562, and HL60), and two primary
human cell lines (CCD112 CoN and CCD841 CoN). All cell lines
were characterized by cellular morphology and DNA ﬁngerprint-
ing, and examined to ensure that they were free of mycoplasma
with LookOut Mycoplasma PCR Detection Kit (Sigma-Aldrich,
latest test in June, 2017). Karyotype information was obtained
from the NCI database and the COSMIC dataset at the Sanger
Institute. All human cells were cultured in RPMI (Invitrogen)
supplemented with 10% FBS, 2 mmol/L L-glutamine, and
100 U/mL penicillin/streptomycin and maintained at 37C with
5% CO2 in a humidiﬁed environment.
Reagents
Chemicals applied to target sphingolipid pathways were:
DL-PDMP (Cayman Chemical), an inhibitor for glucosylcera-
mide synthase (UGCG); myriocin (Sigma-Aldrich), an inhibitor
for serine palmitoyltransferase; fumonisin B1 (Biomol), an inhib-
itor for ceramide synthase; altenusin (Enzo), an inhibitor for
neutral sphingomyelinases. C8-ceramide (Biomol) is a cell-per-
meable analogue of ceramides. Taxol (TOCRIS) binds to b-tubu-
lin and causes cell-cycle arrest. Antibodies were obtained from the
following sources: anti-UGCG (12869-1-AP, ProteinTech), anti-
SGMS1 (19050-1-AP, ProteinTech), anti-SMPD1 (14609-1-AP,
ProteinTech) and anti-ASAH1 (11274-1-AP, ProteinTech); anti-
CERS1 (ARP49654_P050, Aviva Systems Biology); anti-GAPDH
(60004, ProteinTech), anti-mouse secondary antibody (A9044,
Sigma-Aldrich), and anti-rabbit secondary antibody (A9169,
Sigma-Aldrich).
Library screen
ICCB compound library test (Institute of Chemistry and Cell
Biology, Harvard Medical School, Boston, MA). The screen was
carried out in a 384-well format, with approximately 1,000 MEFs
seeded 24 hours before chemicals were applied. After 72 hours of
treatment, relative cell numberwas determinedwithCellTiter-Glo
luminescent cell viability assay. Summary of compound effect in
aneuploid Ts13 MEF compared with euploid wild-type MEFs is
listed in Supplementary Table S1.
Cell viability assay
Todetermine the effect of various compounds onwild-type and
trisomic MEFs, we performed initial tests using a 96-well Alamar-
Blue viability assay (Invitrogen). Candidates were further ana-
lyzed using the Trypan blue viability assay (Sigma-Aldrich) in a
6-well format. Brieﬂy, cells were plated at a density of 2,000 cells
per well in 96-well plates one day prior to drug treatment. After a
72-hour treatment, each medium was replaced with 100 mL of
fresh medium containing 10% AlamarBlue. Viable cells were
analyzed after 4-hour incubation according to the manufacturer's
instructions. For Trypan blue staining, cells were plated at a
density of 2  105 cells per well in 6-well plates one day prior
to drug treatment. At the indicated time points, cells were trypsi-
nized and mixed with an equal volume of 0.4% Trypan blue and
cell number was counted with the Cellometer Mini and AutoT4
cell counter (Nexcelom). Each analysis was performed at least
three times. SDs are shown.
Apoptosis assay
A total of 1  106 cells were seeded on a 10-cm plate and
exposed to the indicated treatments for 24 hours. Cells were
resuspended in 1 mL Annexin V buffer and further stained with
propidium iodide and FITC-conjugated Annexin V antibody (BD
Pharmingen) for 15 minutes at room temperature prior to FACS
analysis.
Cell proliferation assay
For EdU incorporation analysis, 1 104 wild-type, trisomic, or
Bub1bH/HMEFs were plated onto coverslips coated with 10 mg/mL
ﬁbronectin (Sigma-Aldrich) and allowed to attach to the cover-
slips for 12 hours. Cells were then treated with the indicated
concentrationofDL-PDMPfor48hours andexposed to10mmol/L
EdU during the last 12 hours of treatment. Cells were ﬁxed with
3.7% paraformaldehyde (in PBS) for 15 minutes at room tem-
perature andEdUincorporation intoDNAwas visualizedusing the
Click-iT EdU Alexa Fluor 488 Imaging Kit (Invitrogen) following
manufacturer's instructions.
For Ki67 analysis, 2  105 MIN or CIN cells were seeded into
6-well plates for 24 hours, followed by treatment with the indi-
cated concentration of DL-PDMP for 24 hours. Cells were har-
vested and incubated with anti-Ki67 antibody (BioLegend) for 1
hour at 4C. Cells were washed with PBS before FACS analysis.
Xenograft assay
A total of 4 106 tumor cells were resuspended in 100-mL PBS
and inoculated subcutaneously into single ﬂanks of 6-week-old
female nudemice. Each nudemouse received inoculations of one
MIN cell line in the left ﬂank, and one CIN cell line in the right
ﬂank. Seven days after inoculation, animals were treated with
daily intraperitoneal injections of DL-PDMP (100 mg/kg body
weight) or an equal volume of DMSO vehicle control. Tumor
volumes (mm3) were recorded once a week using the formula
p/6  A  B2 (A is the larger diameter, B is the smaller) to score
tumor progressions.
LC/MS analyses of sphingolipids
Approximately 106 cells were collected in 3-mL ice-cold meth-
anol and lysed and stored at 80C until analysis. Cell lysates
were thawed and brieﬂy centrifuged, then 75 mL cleared cell
extracts were transferred to a vial with 25 mL aqueous solution
containing internal standards (1.0 g/mL 17:0 LPC and 24:0 PC,
Avanti, and 2.0 ng/mL PGE2-d4, Cayman Chemical). LC/MS
analyses were conducted using an Open Accela 1250-Q Exactive
hybrid quadrupole orbitrap LC-MS system (Thermo Fisher Sci-
entiﬁc). Extracts (10 mL) were injected onto an ACQUITY BEH C8
column (1.7 mm, 2.1  100 mm, Waters) that was eluted iso-
cratically at a ﬂow rate of 450 mL/minute for 1 minute with 80%
mobile phase A (5% methanol with 0.1% formic acid, v/v) and
20% mobile phase B (99.9% methanol with 0.1% formic acid,
v/v), followed by a linear gradient to 80% mobile phase B over
2 minutes, then a linear gradient to 100% mobile phase B over
7 minutes. Full scan MS data were acquired over m/z 200–850 at
70,000 resolution in the negative ionmode to proﬁle sphingosine
1-phosphate and over m/z 200–850 in the positive ionization
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mode for all other sphingolipids. Raw data were processed using
TraceFinder software (ThermoFisher Scientiﬁc) for peak detection
and manual review of integrated peaks.
Immunoﬂuorescence microscopy
Cells were ﬁrst ﬁxed with 4% ice-cold paraformaldehyde for
10minutes, then permeabilized with 0.5% Triton X-100 for
5minutes, and subsequently blocked with 5% BSA at room
temperature for 1 hour. Cells were incubated at 4C overnight
with the primary antibody (anti-ceramide, Sigma-Aldrich, 1:200),
followed by a PBS wash. The secondary antibody (Donkey anti-
mouse antibody conjugated to Alexa 488, Thermo Fisher Scien-
tiﬁc, 1:500) was applied for 2 hours at room temperature. Nuclei
were stained with DAPI in antifade mounting medium (Vector
Laboratories). All ﬂuorescence images were acquired using a
Nikon A1 inverted confocal microscope. Single-plane images
were exported with the NIS-Element viewer 4.0 software and
further analyzed using ImageJ. Fluorescence intensities were
determined by subtracting background ﬂuorescence.
Single-cell sequencing analysis
Single MEFs were isolated by microaspiration, and genomic
DNA was ampliﬁed using the GenomePlex Single Cell Whole
Genome Ampliﬁcation Kit (Sigma). AmpliﬁedDNAwas puriﬁed,
barcoded, pooled, and sequenced on an Illumina HiSeq2000 as
described previously (14).
Plasmids
Doxycycline-inducible shRNAs constructs for UGCG and
SGMS1 were generated in pLVX-Tight-Puro plasmid (Clontech)
viaNotI andMluI sites (corresponding oligonucleotide sequences
are listed in Supplementary Table S2). The rtTA-expressing con-
struct pMA2640 (#25434); the helper plasmids for retroviral
production, pUMVC (#8449), and pCMV-VSV-G (#8454); and
the helper plasmids for lentiviral production, pMD2.G (#12259),
and psPAX2 (#12260), were obtained from Addgene.
Protein and quantitative RT-PCR analysis
Cells were lysed and subjected to immunoblot analyses as
described previously (11). Total RNA was extracted using RNeasy
Mini Kit (Qiagen) according to the manufacturer's instructions.
RNA (1 mg)was used for cDNAs synthesis usingOmniscript RTKit
(Qiagen). Quantitative RT-PCR was carried out in a LightCycler
480 II (Roche) using SYBR Green PCR Kit (Qiagen). The Light-
Cycler software was used to determine gene expression levels and
normalized to a ribosomal reference gene, RPL19. Primer
sequences are listed in Supplementary Table S3.
Retroviral and lentiviral transduction
For retrovirus production, 293T cells were transfected with the
pMA2640plasmid, togetherwith thepackagingplasmids pUMVC
and pCMV-VSV-G using Fugene HD transfection reagent (Pro-
mega). Retroviral particles were collected 36–48hours after trans-
fection, and passed through a 0.45-mm ﬁlter to remove cell debris.
After transduction, blasticidin (5 mg/mL) was used to select for
rtTA-expressing stable MIN and CIN cells. Lentiviruses were
generated by cotransfecting the pLVX-Tight-Puro shRNA vectors
together with the packaging plasmids psPAX2 and pMD2.G into
293T cells using the Fugene HD transfection reagent. Lentiviruses
were collected 36hours after transfection. After passing through
0.45-mm ﬁlters, the cleared supernatants were used to transduce
retroviral-targeted MIN and CIN cells for doxycycline-inducible
assays. Puromycin (1 mg/mL) was used for stable cell line
selection.
siRNA knockdown
Silencer oligonucleotides for UGCG (SASI_Hs01_00050364,
00050365, 00050366), SGMS1 (SASI_Hs01_00060990,
00060991, 00060992), and scramble controls were purchased
from Sigma-Aldrich. MIN and CIN cells were transiently trans-
fected with UGCG or SGMS1 siRNA oligonucleotides using Lipo-
fectamine 3000 (Invitrogen) according to the manufacturer's
instructions. mRNA levels were assessed 24 hours after
transfection.
RNAi signatures
An eighth of a million cells in 250 mL B-cell medium (BCM)
of each shRNA-bearing Em-Myc p19arf/ lymphoma cell line
were seeded into 24-well plates. For wells that would remain
untreated as a control, only 1/16th of a million cells were
seeded. Next, 250 mL of medium containing several concentra-
tions of the compound/s as indicated were added to cells. After
24 hours, 300 mL of cells from untreated wells were removed
and replaced by 300-mL fresh BCM. All wells then received
500 mL BCM before being placed in the incubator for another
24 hours. At 48 hours, cells were checked for viability via ﬂow
cytometry on a FACScan ﬂow cytometer (BD Biosciences) using
propidium iodide (PI) as a live/dead marker. The lethal dose
(LD) was determined to be the dose at which that percent of
cells remained PI negative. For single drug signatures, only
doses that elicited an LD80–90 were further diluted with 1 mL
of fresh BCM and analyzed for GFPþ% the next day. However,
for combination doses, the combination dose that achieved
LD80–90 and the single doses that contributed to the combina-
tion were diluted and analyzed 24 hours later.
Relative enrichment and depletion values for each shRNA in
response to drug were then analyzed via a modiﬁed K-nearest
neighbors algorithm to classify compound mechanism of action
(23, 24).
Statistical analysis
Results are presented as the mean  SD. Statistical analyses
were performed using Prism version 5.0 (GraphPad) using an
unpaired two-tailed Student t test. Tumor growth was compared
by ANOVA and patient survival analyses were performed using
log-rank test. Statistical signiﬁcances are labeled as ns, not signif-
icant; , P < 0.05; , P < 0.01; , P < 0.001.
Results
An unbiased chemical screen identiﬁes DL-PDMP as an
aneuploidy-selective proliferation antagonist
Whole chromosome gains and losses cause a number of
cellular stresses, which can be enhanced by further interference
with the cellular pathways affected by aneuploidy (5, 11, 25).
To identify novel vulnerabilities of aneuploid cells, we screen-
ed a library comprised of 2,640 off-patent bioactive com-
pounds for small molecules that preferentially impaired
the proliferation of MEFs trisomic for chromosome 13 (Ts13)
compared with isogenic euploid control MEFs. We found
DL-PDMP, a glucosylceramide synthase inhibitor, to signiﬁcantly
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impair the proliferation of trisomy 13 MEFs, while only mini-
mally affecting the growth of euploid control MEFs (Fig. 2A;
Supplementary Table S1).
To determine whether this antiproliferative effect of DL-PDMP
was speciﬁc to trisomy 13 or whether the compound also inhib-
ited the proliferation of other aneuploid cell lines, we measured
proliferative capacity of trisomy1, 16, and 19MEFs over a range of
DL-PDMP concentrations. This analysis revealed that the prolif-
eration of all trisomic cell lines was preferentially inhibited by the
drug compared with euploid control lines (Fig. 2A). The most
dramatic effects were observed when high drug concentrations of
DL-PDMP (25 and 50 mmol/L) were applied. The anti-
proliferative effects of DL-PDMP on trisomic cells were largely
due to increased apoptosis as judged by an increase in Annexin
V–positive/PI-negative cells (Fig. 2B). To determine whether DL-
PDMPalso interferedwith cell proliferation in aneuploid cells, we
assessed degree of EdU incorporation. EdU incorporation was
decreased in trisomic MEFs irrespective of whether they were
treated withDL-PDMP or not, and similarly in another aneuploid
model,Bub1bH/H (Supplementary Fig. S1A and S1B).We conclude
thatDL-PDMP induces apoptosis inmultipleMEF lines harboring
different trisomies, to a greater extent than in littermate euploid
control MEFs. Colorectal MIN and CIN cell lines did not reveal
cell-cycle progression difference upon DL-PDMP treatment as
judged by Ki67 staining (Supplementary Fig. S1C).
Next, we examined whether DL-PDMP also exhibited cytotox-
icity towards MEF lines that continuously spawn aneuploid cells
of different karyotypes because they carry mutations in genes
essential for accurate chromosome segregation. The spindle
assembly checkpoint (SAC) prevents chromosome segregation
when chromosomes are not correctly attached to the mitotic
spindle (reviewed in ref. 26). Mutations in genes encoding
SAC components thus cause high levels of chromosome mis-
segregation. We utilized MEFs harboring the hypomorphic
BUB1bH/H allele (27) or that express a checkpoint-resistant allele
of CDC20, the chromosome segregation inducer that is inhibited
by the SAC (Cdc20AAA; ref. 28). Both alleles cause chromosome
mis-segregation and the accumulation of cells with single and
multiple chromosome gains and losses in culture over time
(27, 28). We found that primary MEFs carrying these mutations
were also sensitive to DL-PDMP (Fig. 2C). However, the anti-
proliferative effects of DL-PDMP were less dramatic in these cell
lines compared with MEFs harboring constitutive trisomies. This
is most likely due to the fact that only a fraction of Bub1bH/H and
Cdc20AAA MEFs are in fact aneuploid. Single-cell sequencing
showed that 46% and 70%of the BUB1bH/H andCDC20AAAMEFs
are aneuploid (Supplementary Fig. S2). It is also possible that
some speciﬁc aneuploidies confer drug resistance dampening the
cytotoxic effects of DL-PDMP (i.e., 29, 30). We conclude that
DL-PDMP impairs the accumulation of primary cells harboring
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Figure 2.
DL-PDMP inhibits the proliferation of primary aneuploidy cells. A, Euploid wild-type (WT; gray bars) and trisomic MEFs (colored bars) were treated with the
indicated concentrations of DL-PDMP. Cell number was determined after 72 hours. In each experiment, aneuploid MEFs were compared with
euploid littermate control MEFs. To speciﬁcally assess the effects of DL-PDMP on cell proliferation, we normalized cell number of drug-treated cells to that
of the same cells treated with vehicle only. This was necessary because aneuploid cells proliferate poorly. B, Percentage of Annexin V-FITC–positive,
PI-negative cells was determined 24 hours after DL-PDMP treatment. C, Euploid wild-type (gray bars), BUB1bH/H cells (black bars), and CDC20AAA/AAA cells
(open bars) were treated with the indicated concentrations of DL-PDMP. Cell number was determined after 72 hours. In each experiment, aneuploid
MEFs were compared with euploid littermate control MEFs. To speciﬁcally assess the effects of DL-PDMP on cell proliferation, we normalized cell number
of drug-treated cells to that of the same cells treated with vehicle only. This was necessary because aneuploid cells proliferate poorly. The data are shown
as the mean  SD.  , P < 0.05;  , P < 0.01;  , P < 0.001, t test.
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constitutive aneuploidies and primary cells that are chromosom-
ally unstable.
DL-PDMP inhibits the proliferation of highly aneuploid
colorectal cancer cells
Are the cytotoxic effects of DL-PDMP restricted to aneuploid
primary cells or does the compound also induce apoptosis in
aneuploid human cancer cell lines? To address this question, we
compared the effects of the drug on colorectal cancer cell lines
that harbored highly complex karyotypes [chromosome insta-
bility (CIN) cell lines] with that of colorectal cancer cell lines
harboring low levels of aneuploidy [microsatellite instability
(MIN) cell lines; ref. 31]. Colorectal cancer cell lines that exhibit
MIN such as HCT-116, HCT-15, DLD-1, SW48, and LoVo
maintain a close to euploid (pseudodiploid) karyotype (32).
In contrast, colorectal cancer cell lines that display CIN such as
Caco2, HT-29, SW403, SW480, and SW620 harbor chromo-
some numbers ranging from 50 to 96 (33). DL-PDMP prefer-
entially inhibited the proliferation of CIN cell lines compared
with MIN cell lines and euploid control lines (CCD112 CoN
and CCD841 CoN; Fig. 3A). As in aneuploid MEFs, increased
apoptosis appeared to be a cause of the cytotoxic effect of DL-
PDMP. Treatment with the drug dramatically increased apopto-
sis in CIN, but not MIN and euploid control lines (Fig. 3B). As in
aneuploid MEFs, DL-PDMP did not signiﬁcantly antagonize cell-
cycle progression of MIN and CIN cell lines as judged by Ki67
staining (Supplementary Fig. S1C).
The cytotoxic effects of DL-PDMP were also observed in
xenograft experiments. We injected MIN–CIN line pairs
(HC15þSW620; LoVoþHT29) into the ﬂanks of athymic nu/nu
mice and administered DL-PDMP on a daily basis for four weeks.
While the CIN cell lines SW620 and HT29 failed to form subcu-
taneous tumors, MIN cell line growth was only minimally inhib-
ited by DL-PDMP (Fig. 3C and D; Supplementary Fig. S3).
To conﬁrm that the cell death–inducing effects of DL-PDMP in
CIN colorectal cancer cells were at least in part due to the drug's
inhibitory effects on glucosylceramide synthase we examined
the consequences of knocking down expression of UGCG, the
gene encoding glucosylceramide synthase. shRNA- and siRNA-
mediated knockdown led to a signiﬁcant decrease in UGCG
mRNA levels (Supplementary Fig. S4A and S4B) and inhibited
proliferation in highly aneuploid CIN colorectal cancer cell lines,
but not near-euploid MIN colorectal cancer cell lines (Fig. 3E).
Our results indicate that DL-PDMP impairs the proliferation of
CIN colorectal cancer cells at least in part by inhibiting glucosyl-
ceramide synthase.
We also examined the effects of DL-PDMP on the myeloid
lineage malignancies acute (AML) and chronic myeloid leuke-
mia (CML). In these hematopoietic malignancies, we did not
observe a differential effect of DL-PDMP on aneuploid and near
diploid/diploid cancer cell lines. Both Kasumi-1 and HL60 cell
lines (diploid or near diploid) and KU812 and K562 cell lines
(aneuploid) exhibited equally high sensitivity to the drug
(Supplementary Fig. S5A). In contrast, CD34þ hematopoietic
stem/progenitor cells (HSPC) isolated from cord blood (34)
were not sensitive to high doses of DL-PDMP (50 mmol/L;
Supplementary Fig. S5B). These results indicate that leukemic
cell lines are highly sensitive to sphingolipid dysregulation
irrespective of whether or not they are aneuploid and raise the
possibility that DL-PDMP's aneuploidy-selective cytotoxicity is
cell type–speciﬁc.
Aneuploidy causes an increase in intracellular ceramide levels
A key question arising from our observations is why aneuploid
MEFs and CIN colorectal cancer cells are more sensitive to
DL-PDMP than euploid or pseudodiploid cells. DL-PDMP is a
ceramide analogue that inhibits glucosylceramide synthase, thus
decreasing ceramide glycosylation and causing the accumulation
of ceramides that inhibit proliferation and promote differentia-
tion and apoptosis (reviewed in ref. 19). We reasoned that
ceramide levels were already elevated in aneuploid MEFs and
CIN cell lines making them more sensitive to compounds that
increase intracellular ceramide levels. To test this hypothesis, we
quantiﬁed C16-ceramide, C18-ceramide, sphingosine, sphingo-
sine 1-phosphate, dihydrosphingosine, and sphingomyelins in
aneuploid and euploid cells bymass spectrometry. C16-ceramide
appeared to be especially responsive to DL-PDMP addition
increasing signiﬁcantly in both primary aneuploid MEFs and CIN
colorectal cancer cell lines (Fig. 4A and B; Supplementary Fig. S6).
Importantly, C-16 ceramide levels were elevated in trisomic MEFs
compared with euploid control MEFs even before DL-PDMP
treatment (Fig. 4A). This increase in basal C16-ceramide levels
was even more dramatic in CIN colorectal cancer cells when
compared with MIN lines (Fig. 4B). Quantiﬁcation of ceramide
levels using an anti-ceramide antibody revealed similar results
(Fig. 4C). We conclude that C16-ceramide levels are elevated in
aneuploidMEFs andCIN colorectal cancer cells and speculate that
higher levels of aneuploidy are responsible for the stronger
response of CIN cell lines to DL-PDMP compared with trisomic
MEFs.
Increasing intracellular ceramide levels inhibits the
proliferation of aneuploid cells
Our results raise the possibility that DL-PDMP impairs prolif-
eration of aneuploid MEFs and CIN colorectal cancer cells by
increasing intracellular ceramide levels. To test this idea we
examined the effects of the cell-permeable C8-ceramide, on the
growth of aneuploid cells. This analysis revealed that C8-
ceramide, like DL-PDMP, preferentially inhibited the prolifera-
tion of trisomic MEFs and CIN colorectal cancer cells (Fig. 5A and
B; note that C-8-ceramide was also identiﬁed to be aneuploidy
selective in our compound screen; see Supplementary Table S1).
Downregulation of enzymes that metabolize ceramide into
other sphingolipids revealed similar results. Knocking down
expression of SGMS1, the gene encoding sphingomyelin
synthase, which metabolizes ceramide into sphingomyelin
(35), led to a signiﬁcant decrease in SGMS1 mRNA levels (Sup-
plementary Fig. S4C) and inhibited proliferation of highly aneu-
ploidCIN colorectal cancer cell lines, but not of near-euploidMIN
colorectal cancer cell lines (Fig. 5C). Inhibition of both, sphingo-
myelin synthase and glucosylceramide synthasehad an evenmore
dramatic effect on the proliferation of CIN colorectal cancer cell
lines (Fig. 5D).We conclude that C16-ceramide levels are elevated
in trisomic MEFs and CIN colorectal cancer cells and that this
sensitizes aneuploid cells to chemical perturbations that elevate
intracellular ceramide levels.
The ceramide salvage and sphingomyelin hydrolysis pathways
contribute to high ceramide levels in aneuploid cells
Why are ceramide levels increased in aneuploid MEFs and CIN
colorectal cancer cells? To begin to address this question, we
examined the consequences of inhibiting various ceramide syn-
thesis pathways. Ceramides are synthesized by three major
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Figure 3.
DL-PDMP antagonizes the growth of CIN colorectal cancer cell lines. A, Human colorectal cancer cell lines were treated with the indicated concentrations
of DL-PDMP. Cell number was determined 72 hours after compound addition. To speciﬁcally assess the effects of DL-PDMP on cell proliferation,
we normalized cell number of drug-treated cells to that of the same cells treated with vehicle only. B, Percentage of Annexin V-FITC–positive, PI-negative
cells was determined 24 hours after DL-PDMP treatment. C and D, Mice were inoculated with 4  106 MIN cells on the left ﬂank and an equal number of CIN
cells on the right ﬂank. Seven days after injection (indicated by the arrow in C), mice were treated with daily intraperitoneal injections of DL-PDMP
or vehicle (n  6 per group). Tumor volume (mm3) was measured at the indicated time points and is shown as mean tumor volumes. Mice treated with
vehicle (left) or DL-PDMP (right) 28 days after transplantation are shown inD. E,MIN and CIN cancer cell lineswere transfectedwith shRNA (top) or siRNAs (bottom)
constructs targeting UGCG for 72 hours and cell number was determined. Cell number was normalized to vector control–transfected cells. The data are
shown as the mean  SD.  , P < 0.05;  , P < 0.01;  , P < 0.001, t test.
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pathways. In the de novo synthesis pathway, ceramide is produced
via the condensation of serine and palmitate through serine
palmitoyltransferase and ceramide synthase (Fig. 1). The salvage
pathway either reutilizes long-chain sphingoid bases to form
ceramide through ceramide synthase or by the hydrolysis of
glucosylceramide via glucosyl ceramidase (Fig. 1). In the sphin-
gomyelin hydrolysis pathway, ceramide is producedby the hydro-
lysis of sphingomyelin through sphingomyelinase. Inhibitors
have been developed for all the major enzymes in the three
ceramide biosynthesis pathways.
To determine which ceramide synthesis route(s) is responsible
for the accumulation of C16-ceramide in aneuploid cells, we ﬁrst
examined the consequences of inhibiting de novo ceramide syn-
thesis by treating cells with myriocin, an inhibitor of serine
palmitoyltransferase (36). We found that addition of myriocin
caused a decrease in C16-ceramide levels in trisomic MEFs and
CIN colorectal cancer cell lines (Fig. 6A and B). However, treat-
ment of trisomic MEFs and CIN colorectal cancer cell lines with
the palmitoyltransferase inhibitor did not have a signiﬁcant effect
on the proliferation of the cell lines (Fig. 6C). In contrast,
treatment of cells with fumonisin B1, which interferes with both
de novo synthesis of ceramides and production of ceramides via
the salvage pathway, provided a slight growth advantage to
trisomicMEFs andCINcolorectal cancer cells (Fig. 6D). Inhibiting
the sphingomyelin hydrolysis pathway by treating cells with the
sphingomyelinase inhibitor altenusin also subtly improved
the growth of aneuploid cells (Fig. 6E). At high concentrations
(50 mmol/L), CIN colorectal cancer cells are notably less
sensitive than their near-diploid MIN colorectal cancer cell
counterparts.
To further determine whether a particular ceramide biosyn-
thesis pathway was responsible for DL-PDMP cytotoxicity in
aneuploid cells, we examined the consequences of inhibiting
the three individual ceramide biosynthesis pathways on sur-
vival when combined with a DL-PDMP treatment. We found
that inactivation of each of the three pathways subtly relieved
the antiproliferative effects of DL-PDMP in CIN colon cancer
cell lines (Fig. 6F–H), and concluded that all ceramide synthesis
pathways are required for the antiproliferative effects of
DL-PDMP. On the basis of the ﬁnding that inhibition of the
salvage and sphingomyelin hydrolysis pathways subtly
improves cell growth of aneuploid cells, we conclude that these
two pathways play a more substantial role in increasing cer-
amide levels in aneuploid cells.
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Figure 4.
DL-PDMP causes C16-ceramide accumulation in aneuploid cells. A, Mass spectrometry–based quantiﬁcation of C16-ceramide levels in wild-type,
trisomy 13, and trisomy 16 cultures following a 24-hour treatment with 50 mmol/L DL-PDMP or vehicle. Ceramide levels were normalized to those
of wild-type cells treated with vehicle only, which was set to 1. B, Mass spectrometry–based quantiﬁcation of the C16-ceramide levels in MIN and CIN cancer
cell lines following a 24-hour treatment with 50 mmol/L DL-PDMP or vehicle. Ceramide levels were normalized to HCT116 cells treated with vehicle only,
which was set to 1. C, Immunoﬂuorescence imaging of intracellular ceramide in MIN and CIN cancer cell lines following a 24-hour treatment
with 50 mmol/L DL-PDMP or vehicle. Quantiﬁcations of relative ceramide levels are shown on the right. Ceramide levels were normalized to DLD1 cells
treated with vehicle only, which was set to 1. The data are shown as the mean  SD. , P < 0.05;  , P < 0.01;  , P < 0.001, t test.
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Sphingomyelin synthase levels decrease in CIN colorectal
cancer cell lines upon DL-PDMP treatment
Our data suggest that the salvage and sphingomyelin hydro-
lysis pathways are in part responsible for the sensitivity of aneu-
ploid cells to DL-PDMP. We therefore tested the possibility that
changes in the expression of enzymes involved in these path-
ways occur in CIN colorectal cancer cells but not MIN colorectal
cancer cells. Sphingomyelin synthase (SGMS1 and SGMS2),
UGCG, and ceramidase (ASAH1, ASAH2, ACER1 and ACER3)
are the major classes of enzymes that metabolize ceramide
into other bioactive sphingolipids (Fig. 1). RNA levels of these
enzymes were not evidently lowered in aneuploid cells compared
with euploid cells, and expression did not change, or changed
only marginally in response to DL-PDMP treatment in CIN
and MIN colorectal cancer cell lines (Supplementary Fig. S7A).
However, SGMS1, and to some extent UGCG protein levels,
decreased in CIN colorectal cancer cell lines (HT29, SW48) upon
DL-PDMP treatment compared with MIN colorectal cancer cell
lines (HCT15, DLD1; Fig. 7A). Expression of enzymes that pro-
duce ceramides were not signiﬁcantly changed in CIN colorectal
cancer cell lines (Supplementary Fig. S7B and S7C). Together,
these observations raise the possibility that in CIN cancer cells,
sphingomyelin synthase and, to a lesser extent, glucosylceramide
synthase are downregulated by posttranscriptional mechanisms
and that this downregulation contributes to the increased accu-
mulation of ceramide in these cells upon DL-PDMP treatment.
We conclude that decreased expression of enzymes involved in
metabolizing ceramide into other sphingolipids may be one
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Figure 5.
C8-ceramide limits the proliferation of aneuploid cells. A, Euploid wild-type (WT; gray bars) and trisomic MEFs (colored bars) were treated with the indicated
concentrations of C8-ceramide. Cell number was determined after 72 hours. In each experiment, aneuploid MEFs were compared with euploid littermate
control lines. To speciﬁcally assess the effects of C8-ceramide on cell proliferation we normalized cell number of drug-treated cells to that of the same
cells treated with vehicle only. This was necessary because aneuploid cells proliferate poorly. B, Human colorectal cancer cells were treated with indicated
concentrations of C8-ceramide. Cell number was determined 72 hours after compound addition. Cell number of drug-treated cells was normalized to that
of the same cell line treated with vehicle only. C, MIN and CIN cancer cell lines were transfected with shRNA (left) or siRNAs (right) constructs targeting SGMS1 for
72 hours, and cell number was determined. D, Cells were transfected with pooled siRNAs targeting UGCG and SGMS1, and cell number was determined
after 72 hours. Cell number was normalized to vector control–transfected cells. The data are shown as the mean  SD.  , P < 0.05;  , P < 0.01;  , P < 0.001,
t test.
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Figure 6.
Effects of altering sphingolipid metabolism on DL-PDMP sensitivity in aneuploid cells. A, Mass spectrometry–based quantiﬁcation of C16-ceramide levels in
wild-type, trisomy 13, and trisomy 16 cells following a 24-hour treatment with the indicated compounds. Ceramide levels were normalized to those
of wild-type (WT) cells treated with vehicle only, which was set to 1. B, Mass spectrometry–based quantiﬁcation of C16-ceramide levels in MIN and CIN cancer
cell lines following a 24-hour treatment with the indicated compounds. Ceramide levels were normalized to those of HCT116 cells treated with vehicle only,
which was set to 1. C–E,Wild-type and trisomic cells (left and middle) and human colorectal cancer cells (right) were treated with the indicated concentrations of
myriocin (C), fumonisin B1 (D), or altenusin (E). Cell number was determined after 72 hours. Cell number of drug-treated cells was normalized to that of
the same cell line treated with vehicle only. F–H, MIN and CIN cancer cell lines were treated with 50 mmol/L DL-PDMP either alone or in combination with
myriocin (0.5 mmol/L; F), fumonisin B1 (5 mmol/L; G), or altenusin (50 mmol/L; H). Cell number was determined after 72 hours. Cell number of drug treated cells
was normalized to that of the same cell line treated with vehicle only. The data are shown as the mean  SD.  , P < 0.05;  , P < 0.01;  , P < 0.001, t test.
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Figure 7.
Effects of altering ceramide levels on cancer development and treatment. A, MIN and CIN colorectal cancer cells were treated with DL-PDMP at the indicated
doses for 24 hours and UGCG and SGMS1 levels were determined by immunoblot analysis. GAPDH served as a loading control. B, Survival analysis
(log-rank test) of colon cancer patients expressing high or low levels of UGCG (left) or SGMS1 (right). Dataset GSE16125 is shown on the top; bottom, data set
GSE17536. C andD,Wild-type MEFs (C) or MIN and CIN colorectal cancer cell lines (D) were treated with the indicated concentrations of DL-PDMP (P) and Taxol (T).
Cell numberwas determined after 72 hours. Cell number of drug–treated cells was normalized to that of cells treatedwith vehicle only. E, Em-Mycp19arf/ lymphoma
cells were treated with Taxol and DL-PDMP. The shRNA signatures generated at LD10 single drug doses, which produce LD80–90 signatures when
combined, are shown at the top. The signature that is produced when the two drugs are combined to yield an LD of 80–90 is shown in the middle
panel. LD80–90 signatures for the single drugs are shown at the bottom. The data are shown as the mean  SD.  , P < 0.001, t test. NS, nonsigniﬁcant.
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reason for the increased sensitivity ofCIN colorectal cancer cells to
compounds that elevate intracellular ceramide levels. We note
however that changes in protein levels of these enzymes do not
appear to be altered in untreated cells, indicating that other
mechanisms must be responsible for increased basal ceramide
levels in CIN colorectal cancer cell lines.
An alternativeway to assess the importance of ceramide-metab-
olizing enzymes in colorectal cancer cell proliferation is to ask
whether expression of these enzymes predicts patient survival.
Speciﬁcally, upregulation of UGCG and SGMS1 ought to cause a
decrease in intracellular ceramide levels and hence increased
tumor growth, which would lead to decreased survival. To test
this possibility, we correlated expression of UGCG and SGMS1
with survival in two colorectal cancer studies (37, 38). Analyses of
clinical datasets GSE16125 and GSE17536 revealed that high
levels of UGCG and to some extent SGMS1 are associated with
decreased survival (Fig. 7B). This observation raises the possibility
that upregulation of either or both genes could promote the
survival of aneuploid cancer cells and thus affect morbidity. We
further note that targeting either or both enzymes may have a
therapeutic beneﬁt.
DL-PDMP enhances the cytotoxic effects of the aneuploidy-
inducing chemotherapeutic Taxol
Taxol is the most commonly used chemotherapeutic agent in
the treatment of both solid tumors and hematopoietic malignan-
cies (39). Taxol is a microtubule poison that arrests cells in
mitosis, but induces chromosome mis-segregation at clinically
relevant concentrations (40). If DL-PDMP indeed preferentially
induces apoptosis in aneuploid cells, wepredict that this ceramide
analogue ought to enhance the cytotoxic effects of Taxol.
We treated wild-type MEFs with low concentrations of Taxol,
DL-PDMP, or a combination thereof, and found DL-PDMP to
subtly enhance the toxicity of Taxol (Fig. 7C). The effects of
combining Taxol and DL-PDMP were more striking in MIN
colorectal cancer cell lines and especially evident inCIN colorectal
cancer cell lines (Fig. 7D).
To further characterize the enhancement of Taxol's cytotoxicity
by DL-PDMP, we employed a previously developed method to
examine anticancer drug combination synergy andmechanism of
action (23, 41). In this assay, murine Em-Mycp19arf/ lymphoma
cells harboring eight different shRNA-GFP constructs are treated at
equipotent doses with either a single compound or compound
combinations. The pattern of resistance and sensitivity of these
shRNA-harboring cells to a drug or drug combination is then used
to bioinformatically classify themechanism of action of the drugs
being tested.
For this classiﬁcation, we ﬁrst needed to determine the drug
concentrations required to kill 80%–90% (LD80–90) of the
lymphoma cells. We found that the LD80-90 of DL-PDMP was
between 61 mmol/L and 85 mmol/L. The same degree of
growth inhibition was accomplished at Taxol concentrations of
17 nmol/L to 20 nmol/L. Notably, the LD80–90 of the DL-PDMP
and Taxol combination was achieved at concentrations of
7–14 mmol/L DL-PDMP and 5–6.25 nmol/L Taxol. When applied
individually at these concentrations, the compounds reduced
proliferation by only 10%. The combination of DL-PDMP and
Taxol was the most synergistic combination tested in this system
relative to the Bliss Independence additivity model (41).
To characterize the mechanism of action of the synergistic
DL-PDMP/Taxol combination, we obtained the eight shRNA
signature of cells treated with either compound alone or in
combination. As expected, Taxol classiﬁed as a microtubule
stabilizer signature (Taxol LD80–90; Fig. 7E). This signature is
characterized by increased resistance to the drug upon p53 knock-
down and increased sensitivity upon knockdown of Chk1 and
Bok (Fig. 7E; ref. 41). DL-PDMP classiﬁed as a new previously
uncharacterized mechanism of action, as judged by its eight
shRNA signature. This novel signature is characterized by
increased sensitivity to DL-PDMP upon knockdown of the
PI3K-like ATX (Fig. 7E). The signature of the combination of
DL-PDMP and Taxol classiﬁed as a microtubule stabilizer indi-
cating that DL-PDMP enhances the effects of Taxol. Our results
raise the exciting possibility that compounds that like DL-PDMP
lead to an increase in intracellular ceramide levels could signif-
icantly improve the efﬁcacy of Taxane-based chemotherapeutics.
Discussion
Previous studies have identiﬁed both gene-speciﬁc effects of
aneuploidy as well as phenotypes seen in many different aneu-
ploid cells (42–44). The latter category includes proliferation
defects, proteotoxic and energy stress, as well as genomic insta-
bility. Here, we describe another broadly observed aneuploidy-
associated phenotype—dysregulation of sphingolipid metabo-
lism that results in elevated levels of ceramide. An unbiased
chemical genetic approach identiﬁed two compounds that
increase intracellular ceramide levels, DL-PDMP and C8-
ceramide, to induce apoptosis in aneuploid primary and cancer
cell lines. Our data further indicate that one reason for this
increased sensitivity is that aneuploid cells already harbor elevat-
ed levels of this proapoptotic lipid. Importantly, the adverse
effects of ceramide on the proliferation of aneuploid cells appear
conserved across species. In an unbiased genetic selection, Torres
and coworkers identiﬁed mutations that cause a decrease in
intracellular ceramide levels to improve the ﬁtness of aneuploi-
dy-budding yeast cells (ref. 45; E.M. Torres, personal communi-
cation). Thus, two nonhypothesis-driven approaches in different
experimental systems have uncovered the same biological process
as being deregulated and causing a ﬁtness defect in aneuploid
cells. These observations lend support to the idea that large-scale
changes in a cell's karyotype and hence proteome impact cell
physiology in fundamentally the same way in all eukaryotes.
A key question posed by our results is why ceramide levels are
elevated in aneuploid cells. We ﬁnd that inhibition of all three
ceramide synthesis pathways, the de novo synthesis pathway, the
salvage pathway and the sphingomyelin hydrolysis pathway, are
required for DL-PDMP–induced apoptosis in aneuploid cells.
This ﬁnding indicates that all three pathways contribute to high
levels of ceramide in aneuploid cells. However, the fact that
chemical inhibition of the salvage pathway and the sphingomye-
lin hydrolysis pathway, but not of the de novo synthesis pathway
improves the proliferation of trisomic cells, suggests that these
two pathways are particularly important for the accumulation of
ceramides in aneuploid cells.
Why baseline ceramide levels are higher in aneuploid cell lines
remains unknown. The abundance of enzymes involved in the
biosynthesis and metabolism of ceramides is not noticeably
altered in aneuploid cells. This ﬁnding indicates that enzyme
activities rather than levels are altered in aneuploid cells. Consis-
tent with this conclusion are previous studies that showed DNA
damage stress to cause ceramide accumulation by affecting the
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activity of ceramide-producing and -metabolizing enzymes. In
HeLa and U937 cells, UV irradiation triggers the hydrolysis of
sphingomyelin by acid sphingomyelinase thereby raising intra-
cellular ceramide levels (46). The DNA-damaging agent dauno-
rubicin has been shown to stimulate de novo synthesis of ceramide
via activation of ceramide synthase (47). Aneuploid cells experi-
ence a number of stresses includingDNAdamage (8).Wepropose
that it is these aneuploidy-associated stresses that alter the activity
of ceramide biosynthesis and metabolizing enzymes thereby
causing an increase in intracellular ceramide levels. When aneu-
ploid cells are treated with DL-PDMP or C8-ceramide, the cer-
amides accumulate to even higher levels and induce apoptosis by
previously described mechanisms (48). It is also possible that
DL-PDMP induces yet further alterations in ceramidemetabolism
in aneuploid cells. In this regard, we note that levels of two
enzymes critical for themetabolismof ceramides intoother lipids,
UGCGand SGMS1, do decrease upon treatment of CIN colorectal
cancer cells with DL-PDMP.
Our results indicate that aneuploid primary cells are more
sensitive to increased ceramide levels than euploid cells. A similar
differential sensitivity is seen in colorectal cancer. Highly aneu-
ploid CIN cancer cell lines were more sensitive to DL-PDMP and
C8-ceramide than pseudo-diploid MIN cancer cell lines. This
differential sensitivity of aneuploid and pseudo-diploid cell lines
does, however, not exist in all cancer types. Myeloid leukemia cell
lines are very sensitive to DL-PDMP treatment irrespective of
whether or not they are aneuploid. The absence of a differential
effect in this cancer may be due to the fact that all myeloid
leukemias are sensitive to ceramides for additional reasons.
Metabolizing ceramide into other lipids is central for myeloid
leukemia cells to proliferate (49). Consistent with this ﬁnding,
SGMS1activity has been shown tobeupregulated by theBCR-ABL
oncogene, the cause of CML (50). In the AML cell line HL-60,
SGMS1 activity is also upregulated (50). Finally, mutations in the
neutral sphingomyelinase (nSMase) gene SMPD3, which encodes
a primary ceramide biosynthesis enzyme, were identiﬁed in 5 of
92 AMLs and 8 of 131 acute lymphoid leukemias (ALL), but not
in other tumor types (51). Together, our ﬁndings and that of
others suggest that aneuploidy sensitizes some cells types to
increasing intracellular ceramide levels. In other cell types,
ceramide sensitivity may already be so high that karyotype no
longer matters.
Ceramide biosynthesis regulation has been shown to be clin-
ically relevant in cancer. The ﬁrst report of a role of sphingolipid
metabolism in tumorigenesis was published more than 30 years
ago (52). Since then it has become clear that this lipid synthesis
pathway contributes to disease progression and outcome inmany
different cancers. In human gliomas, low levels of ceramide are
associated with poor outcome (53). A similar correlation was
described in ovarian cancer. In this tumor type, ceramide levels are
reduced compared with normal ovarian tissues and tumors har-
bor biologically inactive dihydroceramide instead (54). Our
analyses of two colorectal cancer datasets also support the idea
that low levels of ceramide are associated with aggressive disease.
Targeting sphingolipid metabolism has been explored in a
variety of clinical contexts including obesity, type II diabetes,
Gaucher disease, and cancer (55). In the case of glioblastoma, for
example, increasing ceramide levels has been suggested as a
therapy following relapse after chemo- or radiotherapy. Recurrent
glioblastomas harbor high levels of sphingosine kinase activity.
Targeting sphingosine kinase (SK) would prevent conversion of
ceramide into sphingosine 1-phosphate (S1P) hence causing an
increase in ceramide levels and apoptosis (22).Our study suggests
that the aneuploid state causes an increase in intracellular cer-
amide levels. Given thatmost solid human tumors are aneuploid,
treatments that elevate intracellular ceramide to levels where the
lipid induces apoptosis could represent a new cancer therapywith
ideal properties—broad-spectrum efﬁcacy and selectivity. To
explore this avenue, it is important to understand howDL-PDMP
increases intracellular ceramide levels. DL-PDMP is a ceramide
analogue that is thought to inhibit glucosylceramide synthase
(16) thereby preventing the conversion of ceramide into gluco-
sylceramide. However, DL-PDMP may also interfere with the
function of other ceramide-metabolizing enzymes: DL-PDMP
has been suggested to partially inhibit SGMS as well (56). It has
not escaped our attention that DL-PDMP potentially targeting
multiple enzymes would make the development of high-afﬁnity
inhibitors with DL-PDMP's properties challenging.
We are nevertheless intrigued by the possibility that increasing
intracellular ceramide levels synergizes with the chemotherapeu-
tic Taxol, which at clinically relevant concentrations causes chro-
mosome mis-segregation (40). The effects of combining Taxol
with DL-PDMP are not uniform across cell lines. We ﬁnd that
combining Taxol andDL-PDMPdramatically reduces the effective
dose of Taxol in CIN cell lines and Em-Mycp19arf/ lymphoma
cells, but augmentation was modest in MEFs and MIN cell lines.
Why the response varies between cell types is not yet clear. We
speculate that degree of aneuploidy could at least in part dictate
sensitivity to combination treatment. Recall, primary cell lines in
which only a fraction of cells are aneuploid (BUB1bH/H and
CDC20AAA MEFs) show limited sensitivity to DL-PDMP presum-
ably because a good fraction of cells in the population is euploid.
A similar logic could apply to euploid or pseudodiploid cells
treated with low doses of Taxol. Low doses of Taxol cause
aneuploidy in only a fraction of cells, limiting the impact of
DL-PDMP treatment.
In closing, we note that reduction in effective dose is not only
observed when Taxol was combined with DL-PDMP but also
when Taxol is combined with C8-ceramide. This ﬁnding indicates
that it is indeed elevated levels of ceramide that make Taxol more
cytotoxic. This observation raises the exciting possibility that
combining compounds that increase the intracellular ceramide
levelswith Taxane-based chemotherapeutics couldnot only create
highly effective treatment regimens but may also serve as an
excellent way to mitigate the serious side effects associated with
taxane-based chemotherapies.
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